Last updated on November 2017

A 26-week randomized, open-label, active controlled, parallel-group, study assessing the efficacy and safety of the insulin glargine/lixisenatide fixed ratio combination in adults with Type 2 Diabetes inadequately controlled on GLP-1 receptor agonist and metformin (alone or with pioglitazone and/or SGLT2 inhibitors), followed by a fixed ratio combination single-arm 26-week extension period


Brief description of study

A 26-week randomized, open-label, active controlled, parallel-group, study assessing the efficacy and safety of the insulin glargine/lixisenatide fixed ratio combination in adults with Type 2 Diabetes inadequately controlled on GLP-1 receptor agonist and metformin (alone or with pioglitazone and/or SGLT2 inhibitors), followed by a fixed ratio combination single-arm 26-week extension period

Detailed Study Description

Diabetes type 2 must be on metformin and a GLP1 (victoza, byetta, bydureon, etc..)

Clinical Study Identifier: TX14617

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

American Institute of Research

American Institute of Research
Los Angeles, CA USA
  Connect »